Danaher Reports Q2 Beat but Margin Compression Sparks Selloff

What happened

Danaher reported Q2 revenue of $6.3 billion, up 5.5% year-over-year, and adjusted earnings per share of $1.94, both surpassing analyst expectations. Adjusted core revenue increased 3%, or 4.5% excluding respiratory testing revenue, marking a 150-basis-point acceleration from Q1. The company generated $1.3 billion in free cash flow during the quarter and $2.4 billion in the first half, with year-to-date free cash flow to net income conversion of 124%. Life Sciences posted its strongest quarter in several years, with core revenue up 5.5%, driven by improving customer demand, product innovation, and double-digit growth in high-growth markets including mid-single-digit expansion in China. However, adjusted operating margin fell sharply to 18%, a decline of 9.3 percentage points from the prior-year quarter, signalling that expenses grew much faster than sales. Interest expense rose to $107 million from $71 million a year earlier, reflecting higher financing costs from the Masimo acquisition, which closed earlier than expected. Management raised the full-year adjusted earnings outlook to $8.45 to $8.60 per share, up slightly from the prior range, largely due to the timing of the Masimo deal. However, the company guided for 2% to 3% core revenue growth in Q3, a stepdown from the Q2 pace, citing continued headwinds from customer-project timing in bioprocessing.

Why it matters

The sharp margin compression overshadowed the earnings beat and raised investor concerns about cost control and operational efficiency, particularly as the company navigates integration of the Masimo acquisition and ongoing softness in bioprocessing. The Q3 guidance for slower core revenue growth-well below the Q2 pace-signals near-term uncertainty despite healthy order trends, including mid-teens growth in bioprocessing orders. For a company historically valued for its profitability and consistent execution, the erosion in operating margin and the stepdown in revenue momentum challenge the growth narrative. The raised full-year earnings outlook was driven largely by the timing of the Masimo deal rather than core operating improvements, limiting its reassurance for investors. Life Sciences' strong performance and continued strength in microelectronics and automation are positives, but investors now face questions about whether Danaher can restore margin expansion while managing elevated financing costs and near-term growth headwinds.

Bigger picture

Danaher's results reflect broader dynamics in the life sciences and diagnostics sector, where demand is recovering unevenly. Large pharma and biopharma customers remain healthy, biotech funding is improving, and academic and government markets are stabilising, but bioprocessing-a key growth driver in recent years-continues to face project-timing challenges. The company's exposure to high-growth markets, particularly China, remains a source of resilience, though geopolitical and macroeconomic uncertainties persist. The Masimo acquisition expands Danaher's footprint in specialty diagnostics and patient monitoring, aligning with the secular shift toward AI-enabled healthcare technologies, but also adds near-term integration complexity and higher interest costs. Across the sector, companies are balancing innovation investments-such as automation, AI-driven drug discovery, and semiconductor-related filtration solutions-with margin discipline amid uneven end-market recovery. The margin pressure Danaher experienced underscores the importance of cost discipline as companies navigate a slower-growth environment and digest recent M&A activity.

What to watch

Investors should monitor Q3 core revenue growth to see if the 2% to 3% guidance proves conservative or signals a more prolonged slowdown. The trajectory of bioprocessing order trends and project timing will be critical, particularly whether the mid-teens order growth translates into revenue acceleration later in the year. Operating margin trends in Q3 and beyond will be closely scrutinised to assess whether the Q2 compression was a one-time event or the start of a longer-term challenge. Progress on the Masimo integration, including revenue synergies and cost management, will shape the narrative around the acquisition's value. Updates on demand in high-growth markets, especially China, and continued strength in microelectronics and automation will provide insight into whether Danaher can sustain momentum in its higher-growth businesses. Finally, commentary on customer demand across pharma, biotech, and academic markets will signal whether the recovery is broadening or remains uneven.